At Genet, we offer the “Oncomine Tumor Mutation Load Assay,” a cutting-edge service designed to identify cancer driver variants and evaluate tumor mutational burden (TMB), a promising immuno-oncology biomarker, utilizing next-generation sequencing technology. Immune checkpoint […]
An abnormal mass of tissue that usually does not contain cysts or liquid areas. […]
Myeloid disorders comprise a diverse group of hematologic conditions, including various forms of leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. At Genet, we are committed to advancing clinical research in the field of myeloid disorder genetics. […]
Liver Cancer Research Liver cancer is a malignant condition that originates in the liver cells, with hepatocellular carcinoma being the most common form. At Genet, we are dedicated to advancing clinical research in the field […]
The following targets are included in the Oncomine™ HRR Pathway Predesigned Panel:
At Genet, we are committed to advancing clinical research in the field of gastric and esophageal cancer genetics. Our research services focus on various aspects, including: Please note that the information and services provided on […]
@ Genet Canada Corporation | Website content is for educational and research purposes only and is not intended to be used for medical advice, diagnosis or treatment.